Factors associated with endometrial bleeding in continuous hormone replacement therapy

Menopause

Volumn 9, Issue 3, 2002, Pages 188-194

  Shau, Wen Yi ^a   Hsieh, Ching Chang ^a   Hsieh, T'sang T'ang ^a   Hung, Tai Ho ^a   Huang, Kuo En ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Endometrium; Hormone replacement therapy; Risk factors

Indexed keywords

CONJUGATED ESTROGEN; FOLLITROPIN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; AMENORRHEA; ARTICLE; BLEEDING; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PROSPECTIVE STUDY; RISK FACTOR; TRANSVAGINAL ECHOGRAPHY; UTERUS BLEEDING; UTERUS MYOMA; VAGINA BLEEDING;

EID: 0036244502     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200205000-00007     Document Type: Article

References (26)

1. Hormone replacement therapy and endometrial cancer risk: A metaanalysis
2. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
3. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
4. Estrogen replacement therapy: A survey of women's knowledge and attitudes
5. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors
6. Five years with continuous combined oestrogen/progestogen therapy: Effects on calcium metabolism, lipoproteins, and bleeding pattern
7. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women
8. Combined continuous hormone replacement therapy: A critical review
9. The minimum effective dose of estrogen for prevention of postmenopausal bone loss
10. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate
11. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient
12. Continuous treatment with a combination of estrogen and gestagen: A way of avoiding endometrial stimulation. Clinical experiences with Kliogest
13. Hormone replacement therapy: Effect of progestin dose and time since menopause on endometrial bleeding
14. A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy
15. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities
16. Ultrasonic thickness of the endometrium correlated to body weight in asymptomatic postmenopausal women
17. Relationship between body mass index and transvaginal ultrasonographic endometrial thickness in postmenopausal women
18. Ultrasonic assessment of the endometrium as a predictor of oestrogen status in amenorrhoeic patients
19. Sonographic measurement of endometrial thickness as a predictor of vaginal bleeding in women using continuous combined hormone replacement therapy
20. Disturbances of endometrial bleeding with hormone replacement therapy
21. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy
22. Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women
23. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women
24. Relationship between sonographic endometrial thickness and progestin-induced withdrawal bleeding
25. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial
26. Screening before and during the use of oral contraceptives and hormone replacement therapy